Editorial: Viral vector-based gene therapy in neurological disease: The future is now.

Smith, Jared B; Cancedda, Laura; Jozwiak, Sergiusz; Mercer, Andrew C

Smith, Jared B; Cancedda, Laura; Jozwiak, Sergiusz; Mercer, Andrew C.

Afiliación

Smith JB; Research and Early Development, REGENXBIO Inc., Rockville, MD, United States.
Cancedda L; Brain Development and Disorders Lab, Istituto Italiano di Tecnologia, Genoa, Italy.
Jozwiak S; Research Department, The Children's Memorial Health Institute (IPCZD), Warsaw, Poland.
Mercer AC; Research and Early Development, REGENXBIO Inc., Rockville, MD, United States.

Front Neurol ; 14: 1153681, 2023.

Article en En | MEDLINE | ID: mdl-36864918

Palabras clave

adeno-associated virus (AAV); antibody; gene replacement; gene therapy; promoter; spinal muscular atrophy (SMA); viral vector

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Front Neurol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Front Neurol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos